Alnair is a preclinical stage, platform precision oncology company focused on new methods to treat difficult-to-treat cancers. We developed a first-in-class drug delivery technology that leverages the unique features of cancer metabolism to enhance targeting and penetration of drugs directly to cancer cells, and to improve treatment outcomes for patients.

Cardiosense is building a digital biomarker platform that leverages novel, multi-sensor devices and proprietary algorithms to detect early signs of disease and guide personalized therapy.

CiRC is a privately held, cell therapy company, developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Founded in 2019, CiRC is in pre-clinical development for the use of chemically induced retinal cells for vision restoration and specifically pursuing a treatment for Geographic Atrophy Age-Related Macular Degeneration (“Dry AMD”) and advanced Retinitis Pigmentosa (RP).

ClostraBio is dedicated to creating new therapeutics to treat inflammatory bowel disease (IBD) and food allergy.

Dimension Inx. designs and develops therapeutic products that restore tissue and organ function. Their biomaterials and manufacturing process enables unparalleled design versatility and a nuanced microarchitecture that drives biofunctionality.

A revolutionary platform biotech company, Grove Biopharma operates at the intersection of materials science and medicinal chemistry. Based on the work from the lab of Northwestern University Professor Nathan Gianneschi, Grove focuses on the discovery and development of a new class of biotherapeutics to treat significant unmet medical needs in chronic inflammatory and neurodegenerative diseases.

Inomagen Therapeutics is a private, preclinical stage biotechnology company developing a biological (gene) therapy to improve the treatment of atrial fibrillation.

ReAx is a Chicago-based, pre-clinical company that is applying next generation chemical proteomic platforms to discover, optimize and validate small molecules directly in cells.

Arising from a collaboration between materials scientists and neurological surgeons at Northwestern University, Rhaeos has developed a noninvasive thermal sensor for use in the monitoring of ventricular shunt function. In this manner, they hope to eradicate the uncertainty faced by patients, families and healthcare providers alike.

CRISPR system that enables the manufacture of any therapeutic human cell type from stem cells via sequential, automatic genetic instruction sets.

Zylem Biosciences is a startup biotechnology company developing targeted medicines based on its novel platform technology: A surface chemical mimic of natural high-density lipoprotein (HDL). Zylem has developed a deep pipeline of therapies applicable to diseases and conditions where lipid dysfunction plays a critical role.